CCRM
Lili Aslostovar is a skilled professional in the field of technology, venture development, and cell and gene therapy. With a background in biochemistry and biomedical sciences, Lili has garnered experience in various roles within prominent companies such as CCRM, Treadwell Therapeutics, Inc., and Cytiva. Additionally, serving as a member of the Board of Directors for ASCY, Lili contributes to the Early Childhood Education field by providing resources and support to educators in Hamilton and Haldimand-Norfolk. With a strong educational foundation from McMaster University and Stockholm University, Lili continues to make significant contributions to the research and development landscape.
This person is not in any offices
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.